Press
Scandivir is a privately held company, and therefore information about the company is exclusively distributed to the company's shareholders. Information directed to the market will be found below, as it is released.
For more information, please contact CEO Anders Struksnes at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or +47 911 98 942.
Press information about Ad-36 and the Scandivir joint venture
In the pdf files below you will find information regarding the obesity virus adenovirus 36 (Ad-36) and the research collaboration between Scandivir, SCN, Professor Richard L. Atkinson (Obetech, LLC) and Karolinska Institutet which was announced on April 8, 2008.
PM 080408 AD36 Eng.pdf (PDF: 75kb) Press invitation SCN 080408.pdf (PDF: 72kb) SCN Backgrounder AD36 080408.pdf (PDF: 70kb)
Webcast
More information is also available in the webcast from the press conference held at KI on April 8, 2008, where Professor Atkinson and representatives for Scandivir present the Scandivir and Ad-36 case and answer questions from the present media representatives.
